renal-cell carcinoma (advanced)

systematic review meta-analysis network meta-analysis

Select angiogenesis inhibitorsmTOR inhibitor multi target TKIimmune checkpoint inhibitioninterferonAll mechanism All type of patient       anti-PD-1bevacizumabcombinationmTor inihibitorTKIVEGFR, MET AXL TKI apitolisib atezolizumabcabozantinib tivozanib avelumab axitinibbevacizumabdovitinibeverolimusnivolumabpazopanibpembrolizumabsorafenibsunitinibtemsirolimus       1st line2nd line

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	progression or death (progression free survival PFS) (18)death (overall survival) (13) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	progression or death (progression free survival PFS)	death (overall survival)
angiogenesis inhibitors
bevacizumab
CALGB 90206, 2010	bevacizumab plus interferon alfa	interferon alpha				suggesting
AVOREN, 2007	bevacizumab plus interferon alfa	interferon alpha				suggesting
Yang, 2003	bevacizumab	placebo			Exploratory	-
immune checkpoint inhibition
nivolumab
Chekmate 025 (Motzer), 2015      NCT	nivolumab	everolimus	2L		Risk of bias	suggesting
CheckMate-214, 2017      NCT	nivolumab + ipilimumab	sunitinib	1L		Risk of bias	conclusive
mTOR inhibitor
everolimus
RECORD-1, 2008      NCT	everolimus	placebo				suggesting
RECORD 3, 2014      NCT	everolimus	sunitinib				-
temsirolimus
ARCC (Hudes) temsirolimus alone, 2007      NCT	temsirolimus	interferon alpha				suggesting
INTORSECT, 2014      NCT	temsirolimus	sorafenib				negative
multi target TKI
not classified
Disruptor-1	BNC105P + everolimus	everolimus				-
apitolisib
Powles, 2014	apitolisib	everolimus				-
axitinib
AXIS (Rini), 2011      NCT	axitinib	sorafenib				suggesting
Qin, 2012	axitinib	sorafenib				-
cabozantinib
METEOR, 2015    NCT	cabozantinib	everolimus	after VEGFR-targeted therapy failure	2nd line	Risk of bias	suggesting
CABOSUN, 2017      NCT	cabozantinib	sunitinib	first-line therapy in patients with intermediate- or poor-risk	1st line	Exploratory	suggesting
dovitinib
GOLD      NCT	dovitinib	sorafenib			Risk of bias	negative
pazopanib
Sternberg, 2010	pazopanib	placebo			Low risk of bias	suggesting
VEG105192, 2010        NCT	pazopanib	placebo				suggesting
COMPARZ, 2013      NCT	pazopanib	sunitinib				negative
sorafenib
Escudier, 2009	sorafenib	interferon alpha			Exploratory	negative
TARGET, 2007          NCT	sorafenib	placebo			Low risk of bias	suggesting
Ratain, 2006	sorafenib	placebo			Exploratory	-
sunitinib
Motzer, 2007          NCT	sunitinib	interferon alpha				suggesting
SWITCH      NCT	sunitinib	sorafenib				-
tivozanib
TIVO-1, 2013      NCT	tivozanib	sorafenib				suggesting